Abstract:Background Experience with immune checkpoint inhibitors (ICIs) in the treatment of acute myeloid leukemia (AML) is still limited and based on early clinical trials, with no reported randomized clinical data. In this study, we reviewed the available evidence on the use of ICIs, either in monotherapy or in combination with other treatments, in different AML settings, including newly diagnosed AML, relapsed or refractory (R/R) AML and maintenance treatment after allogeneic-HSCT (allo-HSCT). Materials and Methods A systematic literature review was conducted using PubMed electronic database as primary source to identify the studies involving immune checkpoint inhibitors in first-line and R/R AML. We recorded Overall Response (ORR), Complete Response (CR) and Complete Response with incomplete count recovery (CRi) rates, overall survival (OS) and immune-related adverse events ≥ grade 3 (irAEs). Hereafter, we analyzed the overall profile of these ICIs by performing a meta-analysis of the reported outcomes. Results A total of 13 studies were identified where ICI was used in patients with AML. ORR across these studies was 42% (IC95%, 31% - 54%) and CR/CRi was 33% (IC95%, 22%-45%). Efficacy was also assessed considering the AML setting (first-line vs. relapsed/refractory) and results pointed to higher response rates in first-line, compared to R/R. Mean overall survival was 8.9 months [median 8 months, (IC95%, 3.9 - 15.5)]. Differences between first line and R/R settings were observed, since average overall survival in first line was 12.0 months, duplicating the OS in R/R which was 7.3 months. Additionally, the most specific adverse events (AEs) of these therapies are immune-related adverse events (irAEs), derived from their inflammatory effects. Grade ≥3 irAEs rate was low and similar among studies [12% (95%CI 8% - 16%)]. Conclusion ICIs in combination with intensive chemotherapy, hypomethylating agents or other targeted therapies are gaining interest in the management of hematological malignancies such as AML. However, results obtained from clinical trials are modest and limited by both, the type of design and the clinical trial phase. Hopefully, the prospective study of these therapies in late-stage development could help to identify patients who may benefit from ICI therapy.

Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled

Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Immune checkpoint blockade in hematological malignancies: current state and future potential

Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy

An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!

Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia

Immune-Based Therapeutic Strategies for Acute Myeloid Leukemia

A Review of Efficacy and Safety of Checkpoint Inhibitor for the Treatment of Acute Myeloid Leukemia

Present and Future Role of Immune Targets in Acute Myeloid Leukemia

Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia

Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective

Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress

Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: A Meta-Analysis

Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia

Updates in novel immunotherapeutic strategies for relapsed/refractory AML

The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies

Immune checkpoint inhibitors reverse T-cell functional suppression in the bone marrow of a subset of AML patients

Immunotherapy in Myeloproliferative Diseases

The Immunotherapy of Acute Myeloid Leukemia: A Clinical Point of View

Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors